15:49 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Cushing disease Patient sample and cell culture studies suggest the BRAF V600E inhibitor Zelboraf vemurafenib could help treat Cushing disease, which involves excessive cortisol production triggered by ACTH-secreting pituitary adenomas. In 91 tumor samples...
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
21:24 , Nov 15, 2016 |  BC Week In Review  |  Clinical News

H.P. Acthar Gel: Ph IV started

Mallinckrodt began a U.S. Phase IV trial of H.P. Acthar Gel in about 230 patients. Patients will receive 1 mL H.P Acthar Gel twice weekly for 12 weeks in an open-label part, after which patients...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)

Neurology INDICATION: Anxiety In vitro and mouse studies identified a CRHR1 antagonist that could help treat anxiety. Chemical synthesis and in vitro testing of benzimidazole analogs identified a compound that bound CRHR1 with a Ki...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Novartis, Questcor deal

Questcor completed its acquisition of exclusive, worldwide rights, outside of 13 EU countries, to develop and commercialize Synacthen tetracosactrin and its extended-release formulation Synacthen Depot from Novartis (see BioCentury, June 17, 2013). Synacthen and Synacthen...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Stimulus-triggered acquisition of pluripotency (STAP) cells derived from adult mouse somatic cells Methods to generate mouse STAP cells by exposure to...
08:00 , Feb 27, 2014 |  BC Innovations  |  Tools & Techniques

(Pluri)potent acid

Academics and companies alike are scrambling-and thus far failing-to reproduce a surprisingly simple method for generating pluripotent mouse stem cells that uses an external stress stimulus to trigger reprogramming. Whether the method simply does not...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Signifor LAR pasireotide regulatory update

Novartis disclosed in its 4Q13 earnings that it submitted regulatory applications in the U.S. and EU for Signifor LAR pasireotide to treat patients with acromegaly for whom medical therapy is appropriate. Signifor LAR is a...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
07:00 , Oct 3, 2013 |  BC Innovations  |  Cover Story

Escaping abiraterone

Although numerous papers have detailed how castration-resistant prostate cancers become refractory to Xtandi enzalutamide and other second-generation androgen receptor antagonists, comparatively little is known about how the disease eventually evades CYP17 inhibitors such as Zytiga...